CSL Limited has agreed to acquire Vifor Pharma, a specialty pharmaceutical company, for $11.7 billion.

Vifor is focused on products for iron deficiency, nephrology, and cardio-renal indications. It provides a complementary portfolio across CSL’s current therapeutic areas, including products for hematology and thrombosis, cardiovascular-metabolic, and transplant.

The pending acquisition would add 10 commercialized products to CSL’s portfolio, including Ferinject (ferric carboxymaltose)/Injectafer (ferric carboxymaltose injection), Venofer (iron sucrose), Veltassa (patiromer), and soon Korsuva (difelikefalin).

The combined company would have an expanded pipeline of 37 products across development phases, representing an increase of 37% from CSL’s current standalone pipeline, with up to four product launches expected in 2022/2023.

The transaction, which has been unanimously approved by both companies’ Boards of Directors, remains subject to the various customary closing conditions. It is expected to be completed around mid-2022. The tender offer is expected to begin around January 18, 2022.

Source: CSL and Vifor Pharma